-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-05-28
ELV:NYE- (USD)
COMMON STOCK | Healthcare Plans |
Last Closing
USD 377.95Change
+1.97 (+0.52)%Market Cap
USD 84.11BVolume
2.16MVerdict
Verdict
Values as of: 2025-05-28
COMMON STOCK | Healthcare Plans |
Last Closing
USD 377.95Change
+1.97 (+0.52)%Market Cap
USD 84.11BVolume
2.16MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
UNH | UnitedHealth Group Incorporate.. |
+3.74 (+1.25%) |
USD 268.12B |
CNC | Centene Corp |
-0.08 (-0.14%) |
USD 28.07B |
MOH | Molina Healthcare Inc |
+1.17 (+0.39%) |
USD 16.54B |
OSCR | Oscar Health Inc |
N/A |
USD 4.46B |
NEUE | NeueHealth Inc |
+0.02 (+0.29%) |
USD 0.06B |
CI | Cigna Corp |
+4.59 (+1.47%) |
N/A |
CVS | CVS Health Corp |
+1.26 (+2.01%) |
N/A |
HUM | Humana Inc |
+3.05 (+1.33%) |
N/A |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
CAMX | Cambiar Aggressive Value .. | 5.69 % | 0.00 % |
-0.01 (-0.30%) |
USD 0.06B |
ZWHC:CA | BMO Covered Call Health C.. | 4.88 % | 0.00 % |
-0.15 (-0.30%) |
N/A |
WHCS:SW | iShares MSCI World Health.. | 3.67 % | 0.00 % |
N/A |
N/A |
CBUF:F | iShares V Public Limited .. | 3.37 % | 0.00 % |
+0.04 (+-0.30%) |
N/A |
AILV | 3.21 % | 0.00 % |
N/A |
N/A | |
WELG:XETRA | Amundi S&P Global Health .. | 2.53 % | 0.00 % |
+0.06 (+-0.30%) |
N/A |
WELS:XETRA | Amundi S&P Global Health .. | 2.53 % | 0.00 % |
+0.07 (+-0.30%) |
N/A |
FEGE | The RBB Fund Trust | 2.35 % | 0.00 % |
-0.12 (-0.30%) |
N/A |
H41D:XETRA | HSBC MSCI World Value ESG.. | 2.16 % | 0.00 % |
-0.04 (-0.30%) |
N/A |
ESGI:AU | VanEck MSCI International.. | 1.96 % | 0.00 % |
-0.09 (-0.30%) |
USD 0.19B |
VMAX | REX VolMAXX Long VIX Futu.. | 1.80 % | 0.00 % |
+1.23 (+-0.30%) |
USD 0.05B |
PAPI | Morgan Stanley ETF Trust | 0.70 % | 0.00 % |
-0.28 (-0.30%) |
USD 0.19B |
IHF | iShares U.S. Healthcare P.. | 0.00 % | 0.43 % |
+0.40 (+-0.30%) |
N/A |
FHI:CA | CI Health Care Giants Cov.. | 0.00 % | 0.75 % |
+0.13 (+-0.30%) |
CAD 0.10B |
FHI-B:CA | CI Health Care Giants Cov.. | 0.00 % | 0.00 % |
N/A |
CAD 0.05B |
RYH | 0.00 % | 0.40 % |
N/A |
N/A | |
UBUS:F | UBS (Irl) ETF Public Limi.. | 0.00 % | 0.00 % |
+0.02 (+-0.30%) |
USD 0.15B |
UBUW:F | UBS (Irl) ETF Public Limi.. | 0.00 % | 0.00 % |
N/A |
USD 0.01B |
PBI-B:CA | Purpose Fund Corp. - Purp.. | 0.00 % | 0.00 % |
-0.82 (-0.30%) |
N/A |
TEQI | T. Rowe Price Equity Inco.. | 0.00 % | 0.00 % |
+0.08 (+-0.30%) |
USD 0.30B |
CBUF:XETRA | iShares MSCI World Health.. | 0.00 % | 0.00 % |
+0.05 (+-0.30%) |
N/A |
Market Performance vs. Industry/Classification (Healthcare Plans) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 2.45% | 56% | F | 69% | C- | ||
Dividend Return | 0.46% | 60% | D- | 18% | F | ||
Total Return | 2.92% | 56% | F | 68% | D+ | ||
Trailing 12 Months | |||||||
Capital Gain | -25.24% | 44% | F | 12% | F | ||
Dividend Return | 1.31% | 40% | F | 27% | F | ||
Total Return | -23.93% | 44% | F | 11% | F | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -1.61% | 33% | F | 28% | F | ||
Dividend Return | -0.92% | 22% | F | 20% | F | ||
Total Return | 0.69% | 20% | F | 17% | F | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 11.85% | 89% | A- | 73% | C | ||
Risk Adjusted Return | -7.78% | 22% | F | 19% | F | ||
Market Capitalization | 84.11B | 83% | B | 97% | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector